Please assess the completion status of the following clinical trial:

Trial Title: Pramipexole Versus Placebo in Parkinson's Disease (PD) Patients With Depressive Symptoms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. 15-item Geriatric Depression Scale (GDS) \> or = 5~2. Unified Parkinson's Disease Rating Scale (UPDRS) Part I Score on Question #3 \> or = 2~3. Folsteins Mini-Mental State Examination (MMSE) score \> 24~4. Male or female patient with PD (UK PD Brain Bank criteria).~5. Patients diagnosed with idiopathic PD, Stage I-III by the Modified Hoehn and Yahr Scale and optimally controlled PD symptoms .~6. Male or female patients aged 30 - 80 years.~7. Ability to provide written informed consent.~8. Women of childbearing potential must have a negative serum beta-humanchoriongonadotropin (Beta-HCG) pregnancy test at the Screening visit unless surgically sterile or last menstruation \>or = 12 months prior to signing informed consent.~9. Women of childbearing potential must be using an accepted contraceptive.~10. Patients who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.~Exclusion Criteria:~1. Previous history of allergic response, lack of efficacy or complications with pramipexole or its excipients.~2. History of suicidal attempts in the last twelve months; presence of suicidal tendencies/potential.~3. Atypical PD syndromes due to drugs, metabolic disorders, encephalitis or degenerative diseases.~4. History of PD stereotactic brain surgery.~5. Surgery within 180 days of randomization that would negatively impact the patients participation in the study.~6. History of active epilepsy within the past year.~7. Current psychotherapy or behavior therapy while participating the trial~8. Symptomatic orthostatic hypotension prior to randomization.~9. Malignant melanoma or history of previously treated malignant melanoma.~10. Patients who have received typical neuroleptics, metoclopramide, alpha methyldopa, methylphenidate, reserpine, selegiline or amphetamine derivatives within the past 3 months.~11. Patients who have received dopamine agonists within the past 30 days~12. Electroconvulsive therapy during the 90 days preceding the screening visit (Visit 1).~13. Patients who are currently lactating.~14. Participation in other investigational drug studies or use of other investigational drugs within the previous 30 days prior to randomization.~15. Any other laboratory assay abnormality, which could interfere with patient participation or interpretation of results, or could increase the risk for the patient~16. Any other clinically significant medical/psychiatric condition, which could interfere with patient participation or interpretation of results, or could increase the risk for the patient

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- pramipexole (Type: EXPERIMENTAL): A daily dose of pramipexole 0.125 mg t.i.d.; titration-to-response up to 1.0 mg t.i.d.
- placebo (Type: PLACEBO_COMPARATOR): Placebo (matching) tablets

Based on this trial design, predict the completion outcome and termination type (if applicable).